NASDAQ:AUPH - Aurinia Pharmaceuticals Stock Price, Forecast & News

Aurinia Pharmaceuticals' stock was trading at $14.10 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, AUPH stock has increased by 4.3% and is now trading at $14.70. View which stocks have been mosted impacted by Coronavirus.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aurinia Pharmaceuticals in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Aurinia Pharmaceuticals.

Aurinia Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, May 12th 2020. View our earnings forecast for Aurinia Pharmaceuticals.

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) posted its earnings results on Thursday, November, 14th. The biotechnology company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.19) by $0.02. The biotechnology company earned $0.23 million during the quarter, compared to analysts' expectations of $0.05 million. Aurinia Pharmaceuticals had a negative return on equity of 46.84% and a negative net margin of 38,941.82%. View Aurinia Pharmaceuticals' earnings history.

7 brokers have issued 1 year target prices for Aurinia Pharmaceuticals' shares. Their forecasts range from $14.00 to $32.00. On average, they expect Aurinia Pharmaceuticals' share price to reach $24.29 in the next twelve months. This suggests a possible upside of 65.2% from the stock's current price. View analysts' price targets for Aurinia Pharmaceuticals.

Media headlines about AUPH stock have trended somewhat negative this week, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Aurinia Pharmaceuticals earned a media sentiment score of -1.6 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 4.0 out of 10, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near term. View the latest news aboutAurinia Pharmaceuticals.

Aurinia Pharmaceuticals saw a increase in short interest in the month of March. As of March 13th, there was short interest totaling 5,351,000 shares, an increase of 6.6% from the February 27th total of 5,020,000 shares. Based on an average trading volume of 1,716,400 shares, the short-interest ratio is currently 3.1 days. Approximately 6.3% of the shares of the stock are short sold. View Aurinia Pharmaceuticals' Current Options Chain.

Some companies that are related to Aurinia Pharmaceuticals include Perrigo (PRGO), ACADIA Pharmaceuticals (ACAD), Horizon Therapeutics (HZNP), Jazz Pharmaceuticals (JAZZ), Ascendis Pharma A/S (ASND), Bausch Health Companies (BHC), Reata Pharmaceuticals (RETA), Amarin (AMRN), Forty Seven (FTSV), United Therapeutics (UTHR), Evotec (EVTCY), Mirati Therapeutics (MRTX), BridgeBio Pharma (BBIO), Nektar Therapeutics (NKTR) and Global Blood Therapeutics (GBT).

Based on aggregate information from My MarketBeat watchlists, some companies that other Aurinia Pharmaceuticals investors own include Tetraphase Pharmaceuticals (TTPH), NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), Cara Therapeutics (CARA), Array Biopharma (ARRY), Novavax (NVAX), Alibaba Group (BABA), Corbus Pharmaceuticals (CRBP) and Exelixis (EXEL).

Aurinia Pharmaceuticals trades on the NASDAQ under the ticker symbol "AUPH."

Aurinia Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include FMR LLC (7.18%), Point72 Asset Management L.P. (3.22%), Franklin Resources Inc. (1.18%), Franklin Resources Inc. (1.19%), Perceptive Advisors LLC (0.64%) and Goldman Sachs Group Inc. (0.56%).

AUPH stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Franklin Resources Inc., Franklin Resources Inc., Victory Capital Management Inc., SG Americas Securities LLC, Patriot Financial Group Insurance Agency LLC, Bank of Montreal Can, and Ironwood Investment Management LLC.

AUPH stock was bought by a variety of institutional investors in the last quarter, including FMR LLC, Point72 Asset Management L.P., Perceptive Advisors LLC, Renaissance Technologies LLC, Ikarian Capital LLC, Broadfin Capital LLC, Crawford Lake Capital Management LLC, and Schonfeld Strategic Advisors LLC.

Shares of AUPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of AUPH stock can currently be purchased for approximately $14.70.

Aurinia Pharmaceuticals has a market capitalization of $1.65 billion and generates $320,000.00 in revenue each year. The biotechnology company earns $-123,850,000.00 in net income (profit) each year or ($0.89) on an earnings per share basis. Aurinia Pharmaceuticals employs 39 workers across the globe. View additional information about Aurinia Pharmaceuticals.

The official website for Aurinia Pharmaceuticals is http://www.auriniapharma.com/.

Aurinia Pharmaceuticals' mailing address is 1203-4464 MARKHAM STREET, VICTORIA A1, V8Z 7X8. The biotechnology company can be reached via phone at 250-744-2487 or via email at [email protected]